Company Website:
http://www.medxhealth.com/
MISSISSAUGA, Ontario -- (Business Wire)
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert
Stockfleth, Director of the University Department of Dermatology at St.
Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical
Advisory Board. Dr. Stockfleth was previously the Director of the Skin
Cancer Center in Berlin.
“The addition of Dr. Stockfleth to our Medical Advisory Board completes
our group of highly accomplished physicians from around the world. They
are respected thought leaders located in our targeted markets. We are
very fortunate to have access to Dr. Stockfleth’s knowledge and
expertise,” said Scott Spearn, CEO of MedX.
“MedX’s non-invasive skin cancer scanning technology is ground-breaking
and I am honored to be a member of such an esteemed group of
physicians,” Dr. Stockfleth said. “I see first-hand how MedX’s
technology is a game-changer in early detection of skin cancers,” he
added. He noted that his clinic in Bochum receives in excess of 800
calls per day with respect to dermatological issues and has a capacity
to handle only about half of the inquiries.
Dr. Stockfleth’s research on dermatology, oncology and in particular,
skin cancer, has been extensively published in peer-reviewed journals.
He has contributed to the Journal of Infectious Diseases, International
Journal of Cancer, Journal of Investigative Dermatology and The Lancet.
He is also the former European President of Skin Care in Organ
Transplant Patients Network (SCOPE). In 2008 he was one of the founders
of the European Skin Cancer Foundation, which assists in developing and
providing standardized treatments on a European level. Dr. Stockfleth
graduated from the University of Hamburg and is a Jung-Foundation
scholar.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device
and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™,
SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath
suspicious moles and lesions in a pain free, non-invasive manner, with
its software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide drug-free
and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events. The
forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023006008/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President
and CEO
or
Media Relations
Deborah Thompson,
416-918-9551
dthompson@medxhealth.com
Source: MedX Health Corp.
© 2024 Canjex Publishing Ltd. All rights reserved.